Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.50 |
| ▸ | F9 | P00740 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17137741 | 0.86 | EGLN1 (0.48) | MAOBF9F10MAOANR4A2 | |
| SCHEMBL30450790 | 0.86 | EGLN1 (0.48) | MAOBF9F10MAOANR4A2 | |
| Hydrochloric Acid SCHEMBL3047142 | 0.82 | QPCTL (0.43) | QPCTL | |
| SCHEMBL17137537 | 0.82 | EGLN1 (0.48) | MAOBF9F10MAOANR4A2 | |
| SCHEMBL30450030 | 0.82 | EGLN1 (0.48) | MAOBF9F10MAOANR4A2 | |
| SCHEMBL17137714 | 0.81 | IP6K1 (0.44) | MRGPRX4PRMT5 | |
| SCHEMBL17137754 | 0.81 | EGFR (0.49) | MAOBF9PRMT5 | |
| SCHEMBL13373358 | 0.77 | IP6K1 (0.56) | MAOBMAOAPRMT5 | |
| SCHEMBL30450179 | 0.76 | EGLN1 (0.48) | F9NR4A2QPCTLPRMT5 | |
| SCHEMBL17137719 | 0.76 | EGLN1 (0.48) | F9NR4A2QPCTLPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | EGLN3, EGLN2, P4HA1 | MAOB 390/4885F9 3430/4885F10 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.